The updated data presented at the European Hematology Association 2023 supports the safety and efficacy of UCART22 in a heavily pretreated r/r B-ALL population. This positive news is likely to have a positive short-term impact on Cellectis' stock price as it demonstrates the potential of their gene-editing platform and encourages further enrollment into the BALLI-01 clinical study.